Hamoa’s point is that it is uneconomic for a generic - the first generic - to launch - followed 6 months later by two other generics -and maybe more ?? Amarin selling V as cheap as generics can - for if generic can profit from a generic version so to may Amarin ? Is there any profit to be had by launching now ?- even though you may be the first to launch (only a six month gain) - that is the question for Teva. And then if Teva don’t launch do Hikma and Dr R - ?
Or do they all wait until Amarin has developed a big fat market for them to try carve up ?
It’s an interesting question ... another year or two of USA market without completion will help Amarin as to Europe/ Row
Generics want to make money not loose it ... so they have much to consider perhaps Alm
There is no business reason for Amarin to market in the US at this time unless JL has the current situation nailed and reduce-it population can still be saved...
The question is whether there is enough demand in Europe to use all of the existing and additional available supply capacity of API that Amarin currently controls in the EU/ROW until an agreement can be reached with the generics to protect a portion of the US market for it to make sense for Amarin to continue to marketing/eduction process.
News 
Market Data 
Discover 
